Biohaven amends Knopp deal: royalty cut to mid-single digits, milestones reduced by >$800M

Biohaven Ltd.

Removed up to $562.5M in commercial sales milestones; reduced developmental/regulatory milestones from $575M to up to $210M.
Replaced high-single-to-low-teens royalties with flat mid-single-digit royalty for BHV-7000 and pipeline.
Filed prospectus supplement for resale of 3,588,688 common shares issued as consideration for the Knopp Amendment.
Biohaven retains option to pay remaining contingent milestones in cash or shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.